PCM
DYN icon

Pentwater Capital Management’s Dyne Therapeutics DYN Stock Holding History

Pentwater Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-15,000
Closed -$316K – 248
2021
Q2 		$316K Hold
15,000
– – ﹤0.01% 270
2021
Q1 		$233K Buy
+15,000
New +$290K ﹤0.01% 324

Other funds holding DYN

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Pentwater Capital Management's DYN Position: Q3 2021 in Review

Pentwater Capital Management sold out of Dyne Therapeutics (DYN) in Q3 2021, closing a stake of 15,000 shares — an estimated $316K sold.

Pentwater Capital Management first reported a position in DYN in Q1 2021 and held it in 2 quarters. The position peaked at $316K in Q2 2021. 83 funds tracked by Wall St. Rank hold DYN as of Q3 2021.

  • Pentwater Capital Management reported no remaining Dyne Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Pentwater Capital Management sold 15,000 Dyne Therapeutics shares in Q3 2021, an estimated $316K.
  • Pentwater Capital Management first reported a position in Dyne Therapeutics in Q1 2021 and held it in 2 quarters.
  • Pentwater Capital Management's Dyne Therapeutics position peaked at $316K in Q2 2021.
  • 83 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2021.

Based on Pentwater Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.